Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ocrelizumab for Psychoses Possibly Caused by Synaptic Autoimmunity

NCT03971487 is registered in ClinicalTrials.gov with The Methodist Hospital Research Institute as lead sponsor.

NCT NCT03971487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03971487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ocrelizumab for Psychoses Possibly Caused by Synaptic Autoimmunity
Lead sponsor
The Methodist Hospital Research Institute
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 1, 2019
Completion date
October 30, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizo-affective type of psychosis, schizophrenia